Verification of the analytical performance of the urine ecstasy immunoassay on the Abbott Alinity ci ®
1 Mohammed First University, Faculty of Medicine and Pharmacy of Oujda, Morocco.
2 Biochemistry laboratory of Mohammed VI University Hospital, Oujda, Morocco.
Research Article
GSC Biological and Pharmaceutical Sciences, 2025, 30(02), 289-293.
Article DOI: 10.30574/gscbps.2025.30.2.0051
Publication history:
Received on 02 January 2025; revised on 13 February 2025; accepted on 16 February 2025
Abstract:
The precision and reliability of the urine cannabinoids immunoassay on the Abbott Alinity ci® analyzer were systematically evaluated over 30 days in the biochemistry laboratory of Mohammed VI University Hospital. The study consisted of two phases: reproducibility assessment, involving daily measurements at low and high cannabinoid concentrations, and repeatability testing, with 30 replicates per sample. Cannabinoid quantification was performed using a homogeneous immunoenzymatic assay, with data analysis conducted via the BYG middleware, following the manufacturer's guidelines.
The coefficient of variation (CV) for reproducibility ranged from 2.6% to 3.1%, while repeatability CV values varied between 2.8% and 3.7%, all within quality control limits, confirming the assay’s high precision and reliability. These findings underscore the robustness of the Alinity ci® platform for urine cannabinoid analysis, ensuring accurate and reproducible results critical for clinical and forensic applications. By adhering to rigorous analytical performance verification protocols, laboratories can ensure dependable and clinically meaningful outcomes, reinforcing the reliability of urine cannabinoid testing methodologies.
Keywords:
Urine Ecstasy Assay; Abbott Alinity Ci Analyzer; Precision; Reliability; Biochemistry Laboratory
Full text article in PDF:
Copyright information:
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
